Increased toxicities associated with dose escalation of stereotactic body radiation therapy in prostate cancer: results from a phase I/II study

References

• Global burden of disease cancer collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-Adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749–1768.
   PubMed Web of Science ®Google Scholar
• Dasu A, Toma-Dasu I. Prostate alpha/beta revisited-an analysis of clinical results from 14 168 patients. Acta Oncol. 2012;51(8):963–974.
   PubMed Web of Science ®Google Scholar
• Morgan SC, Hoffman K, Loblaw DA, et al. Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline. J Clin Oncol. 2018;36(34):JCO1801097.
   PubMed Web of Science ®Google Scholar
• Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–262.
   PubMed Web of Science ®Google Scholar
• King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013;109(2):217–221.
   PubMed Web of Science ®Google Scholar
• Stone NN, Potters L, Davis BJ, et al. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys. 2007;69(5):1472–1477.
   PubMed Web of Science ®Google Scholar
• Draulans C, van der Heide UA, Haustermans K, et al. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol. 2020;147:92–98.
   PubMed Web of Science ®Google Scholar
• Hannan R, Tumati V, Xie XJ, et al. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-results from a multi-institutional clinical trial. Eur J Cancer. 2016;59:142–151.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute [Internet]. Common terminology criteria for adverse events v4.0. Bethesda (MD): NIH; 2010. [cited 2022 July 25]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
   Google Scholar
• Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–974.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Gospodarowics MK, Wittekind CH. TNM classification of malignant tumors. 7th ed. Hoboken, NJ: Wiley-Blackwell; 2009.
   Google Scholar
• Barry MJ, Fowler FJ, Jr O'Leary MP, et al. The American urological association symptom index for benign prostatic hyperplasia. The measurement committee of the American urological association. J Urol. 1992;148(5):1549–1557; discussion 1564.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network [Internet]. Clinical practice guidelines in oncology. Prostate cancer. Plymouth Meeting (PA): NCCN; [cited 2022 July 25]. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459.
   Google Scholar
• Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385–395.
   PubMed Web of Science ®Google Scholar
• Brand DH, Tree AC, Ostler P, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019;20(11):1531–1543.
   PubMed Web of Science ®Google Scholar
• Kishan AU, Dang A, Katz AJ, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open. 2019;2(2):e188006.
   PubMed Web of Science ®Google Scholar
• Hamstra DA, Mariados N, Sylvester J, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys. 2017;97(5):976–985.
   PubMed Web of Science ®Google Scholar
• Karsh LI, Gross ET, Pieczonka CM, et al. Absorbable hydrogel spacer use in prostate radiotherapy: a comprehensive review of phase 3 clinical trial published data. Urology. 2018;115:39–44.
   PubMed Web of Science ®Google Scholar
• Musunuru HB, Quon H, Davidson M, et al. Dose-escalation of five-fraction SABR in prostate cancer: toxicity comparison of two prospective trials. Radiother Oncol. 2016;118(1):112–117.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Kollmeier M, McBride S, et al. Five-year outcomes of a phase 1 dose-escalation study using stereotactic body radiosurgery for patients with low-risk and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2019;104(1):42–49.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(4):1124–1129.
   PubMed Web of Science ®Google Scholar
• Alayed Y, Davidson M, Quon H, et al. Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy. Radiother Oncol. 2020;144:135–140.
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Taussky D, Menkarios C, et al. Prospective phase II trial of once-weekly hypofractionated radiation therapy for low-risk adenocarcinoma of the prostate: late toxicities and outcomes. Clin Oncol (R Coll Radiol). 2016;28(6):386–392.
   PubMed Web of Science ®Google Scholar
• Quon HC, Ong A, Cheung P, et al. Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): a phase 2 randomized trial. Radiother Oncol. 2018;127(2):206–212.
   PubMed Web of Science ®Google Scholar
• Jackson WC, Silva J, Hartman HE, et al. Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys. 2019;104(4):778–789.
   PubMed Web of Science ®Google Scholar
• Royce TJ, Mavroidis P, Wang K, et al. Tumor control probability modeling and systematic review of the literature of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2021;110(1):227–236.
   PubMed Web of Science ®Google Scholar
• Alayed Y, Cheung P, Pang G, et al. Dose escalation for prostate stereotactic ablative radiotherapy (SABR): late outcomes from two prospective clinical trials. Radiother Oncol. 2018;127(2):213–218.
   PubMed Web of Science ®Google Scholar
• Helou J, D'Alimonte L, Quon H, et al. Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: is there an optimal dose? Radiother Oncol. 2017;123(3):478–482.
   PubMed Web of Science ®Google Scholar